Finanzen von Tyra Biosciences Inc (TYRA)TYRATyra Biosciences Inc

Evaluating the bottom line, Tyra Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -45.31%, provide a clear picture of how effectively TYRA converts its operational activities into shareholder value.

In the context of the broader market, TYRA competes directly with industry leaders such as TRAX and INBX. With a market capitalization of $1.60B, it holds a leading position in the sector. When comparing efficiency, TYRA's gross margin of N/A stands against TRAX's N/A and INBX's N/A. Such benchmarking helps identify whether Tyra Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Tyra Biosciences has reported consistent net losses, with Q2 2026 net income expected to be -$45.56 million. The company's EPS has been negative, with a reported -0.69 in Q2 2026, missing estimates. The current ratio remains high at 14.91, indicating good short-term liquidity, but the overall financial health is concerning due to ongoing losses.